Top-Rated StocksTop-RatedNASDAQ:PCVX Vaxcyte (PCVX) Stock Price, News & Analysis $29.90 -0.11 (-0.37%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$29.92 +0.02 (+0.05%) As of 08/8/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vaxcyte Stock (NASDAQ:PCVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vaxcyte alerts:Sign Up Key Stats Today's Range$29.29▼$30.2750-Day Range$29.90▼$37.3752-Week Range$27.66▼$121.06Volume1.96 million shsAverage Volume1.19 million shsMarket Capitalization$3.88 billionP/E RatioN/ADividend YieldN/APrice Target$136.50Consensus RatingBuy Company Overview Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Read More Vaxcyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScorePCVX MarketRank™: Vaxcyte scored higher than 41% of companies evaluated by MarketBeat, and ranked 660th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxcyte has only been the subject of 1 research reports in the past 90 days.Read more about Vaxcyte's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vaxcyte are expected to decrease in the coming year, from ($4.21) to ($4.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxcyte is -7.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxcyte is -7.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxcyte has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.49% of the outstanding shares of Vaxcyte have been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Vaxcyte has recently decreased by 3.20%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaxcyte does not currently pay a dividend.Dividend GrowthVaxcyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.49% of the outstanding shares of Vaxcyte have been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Vaxcyte has recently decreased by 3.20%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment0.28 News SentimentVaxcyte has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Vaxcyte this week, compared to 8 articles on an average week.Search InterestOnly 2 people have searched for PCVX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows4 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vaxcyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.10% of the stock of Vaxcyte is held by insiders.Percentage Held by Institutions96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vaxcyte's insider trading history. Receive PCVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter. Email Address PCVX Stock News HeadlinesVaxcyte (NASDAQ:PCVX) Shares Gap Down on Disappointing EarningsAugust 8 at 2:47 AM | americanbankingnews.comVaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class ...August 7 at 12:33 AM | finance.yahoo.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 10 at 2:00 AM | Brownstone Research (Ad)Vaxcyte price target lowered to $50 from $85 at TD CowenAugust 7 at 12:33 AM | msn.comVaxcyte (PCVX) Q2 Loss Widens 11%August 6, 2025 | fool.comVaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)August 6, 2025 | globenewswire.comVaxcyte (PCVX) Projected to Post Quarterly Earnings on TuesdayAugust 3, 2025 | americanbankingnews.comVaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in InfantsJuly 31, 2025 | finance.yahoo.comSee More Headlines PCVX Stock Analysis - Frequently Asked Questions How have PCVX shares performed this year? Vaxcyte's stock was trading at $81.86 at the beginning of 2025. Since then, PCVX shares have decreased by 63.5% and is now trading at $29.90. How were Vaxcyte's earnings last quarter? Vaxcyte, Inc. (NASDAQ:PCVX) released its quarterly earnings results on Wednesday, August, 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by $0.10. When did Vaxcyte IPO? Vaxcyte (PCVX) raised $210 million in an IPO on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO and Cantor and Needham & Company were co-managers. Who are Vaxcyte's major shareholders? Vaxcyte's top institutional shareholders include Geode Capital Management LLC (2.33%), Jennison Associates LLC (1.08%), TD Asset Management Inc (0.42%) and Bank of New York Mellon Corp (0.35%). Insiders that own company stock include Jeff Fairman, Jim Wassil, Grant Pickering, Andrew Guggenhime, Mikhail Eydelman, Paul Sauer, Elvia Cowan, Teri Loxam, Heath Lukatch and Halley E Gilbert. View institutional ownership trends. How do I buy shares of Vaxcyte? Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxcyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxcyte investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings8/06/2025Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PCVX CIK1649094 Webwww.vaxcyte.com Phone650-837-0111FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Price Target for Vaxcyte$136.50 High Price Target$163.00 Low Price Target$90.00 Potential Upside/Downside+356.5%Consensus RatingBuy Rating Score (0-4)3.09 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($4.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$463.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-16.55% Return on Assets-15.72% Debt Debt-to-Equity RatioN/A Current Ratio17.70 Quick Ratio17.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$26.52 per share Price / Book1.13Miscellaneous Outstanding Shares129,823,000Free Float125,798,000Market Cap$3.88 billion OptionableOptionable Beta1.21 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PCVX) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.